F0002-ADC / Shanghai Fudan-Zhangjiang - LARVOL DELTA

Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study (ASH 2024) - P1 | "Additionally, F0002 showed potential efficacy in patients previously treated with PD-1/PD-L1 inhibitors. Further exploration of the 3.0 mg/kg dose is warranted to clarify the anti-tumor efficacy of F0002 in PD-1/PD-L1 treated patients."

Clinical • P1 data • Anemia • Classical Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • Thrombocytopenia

A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies. (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | N=23 ➔ 45

Enrollment change • Trial completion • Hematological Disorders • Hematological Malignancies • Oncology • TNFRSF8

A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies. (clinicaltrials.gov) - P1 | N=23 | Recruiting | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Trial primary completion date: Aug 2022 ➔ Dec 2022

Trial primary completion date • Hematological Disorders • Hematological Malignancies • Oncology • TNFRSF8